

¹
D1
concl'd
2. (Twice Amended) A vaccine of claim 1, [when] wherein said *E. coli* strain J5 is of the Rc chemotype.

²
D1
7. (Amended) A method of claim 6, wherein said *E. coli* [is strain J5 (Rc chemotype)] strain J5 is of the Rc chemotype.

11. (Amended) A method of passively conferring upon a second subject protection against infection heterologous Gram-negative bacteria or [LPS-mediated] against lipopolysaccharide (LPS) endotoxin-mediated pathology by the production of an antibody, comprising [the steps of]:

- ³
D1
- a) actively immunizing a first subject with a vaccine comprising a non-covalent complex between (i) purified, detoxified LPS endotoxin derived from *E. coli* and (ii) purified, detoxified outer membrane protein (OMP) derived from *N. meningitidis*;
 - b) collecting from said first subject a post-immune serum or plasma, or IgG isolated therefrom; and,
 - c) administering to said second subject an amount of said serum or plasma or IgG isolated therefrom that is effective in conferring passive protection against a infection by heterologous Gram-negative bacteria [and LPS-mediated pathology] or against lipopolysaccharide (LPS) endotoxin-mediated pathology.

D3
concl^ε 12. A method of claim ¹⁹~~11~~, wherein said *E. coli*
[is strain J5 (Rc ~~chemotype~~)] strain J5 is of the Rc
chemotype.

D4 16. (Amended) A composition of claim 15, wherein
said *E. coli* [is strain J5 (Rc chemotype)] strain J5 is of
the Rc chemotype.
